EPHEDRINE SULFATE Drug Patent Profile

When do Ephedrine Sulfate patents expire, and what generic alternatives are available?

Ephedrine Sulfate is a drug marketed by Amneal, Caplin, Civica, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Mankind Pharma, Ph Health, Renew Pharms, Sagent Pharms Inc, Sandoz, Xiromed, and Zydus Pharms. and is included in nineteen NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one patent family member in one country.

The generic ingredient in EPHEDRINE SULFATE is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ephedrine Sulfate

A generic version of EPHEDRINE SULFATE was approved as ephedrine sulfate by SANDOZ on August 23^rd, 2017.

Summary for EPHEDRINE SULFATE

International Patents:	1
US Patents:	2
Applicants:	15
NDAs:	19
Finished Product Suppliers / Packagers:	19
Raw Ingredient (Bulk) Api Vendors:	13
Clinical Trials:	17
Patent Applications:	446
Drug Prices:	Drug price information for EPHEDRINE SULFATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPHEDRINE SULFATE
What excipients (inactive ingredients) are in EPHEDRINE SULFATE?	EPHEDRINE SULFATE excipients list
DailyMed Link:	EPHEDRINE SULFATE at DailyMed

See drug prices for EPHEDRINE SULFATE

Recent Clinical Trials for EPHEDRINE SULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Second People's Hospital of Huai'an	PHASE1
Instituto Mexicano del Seguro Social	Phase 4
Medical University of Lodz	NA

See all EPHEDRINE SULFATE clinical trials

Pharmacology for EPHEDRINE SULFATE

Drug Class	Norepinephrine Releasing Agent alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Increased Norepinephrine Activity

Medical Subject Heading (MeSH) Categories for EPHEDRINE SULFATE

Adrenergic Agents

Central Nervous System Stimulants

Sympathomimetics

Vasoconstrictor Agents

Anatomical Therapeutic Chemical (ATC) Classes for EPHEDRINE SULFATE

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AB	Sympathomimetics, combinations excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03CA	Alpha- and beta-adrenoreceptor agonists
R03C	ADRENERGICS FOR SYSTEMIC USE
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01FB	Sympathomimetics excl. antiglaucoma preparations
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for EPHEDRINE SULFATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPHEDRINE SULFATE	Injection	ephedrine sulfate	25 mg/5 mL and 50 mg/10 mL	213994	1	2023-03-17
EMERPHED	Injection	ephedrine sulfate	50 mg/10 mL	213407	1	2021-10-14

US Patents and Regulatory Information for EPHEDRINE SULFATE

EPHEDRINE SULFATE is protected by two US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212932-001	Oct 23, 2019	AP	RX	No	No
Renew Pharms	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	208609-001	Mar 1, 2017		DISCN	No	No
Fresenius Kabi Usa	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	209646-001	Aug 4, 2020	AP	RX	No	No
Dr Reddys	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212649-001	Oct 3, 2020	AP	RX	No	No

International Patents for EPHEDRINE SULFATE

See the table below for patents covering EPHEDRINE SULFATE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2021150253

Supplementary Protection Certificates for EPHEDRINE SULFATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
1110543	SPC/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.

Last updated: April 23, 2026

Ephedrine Sulfate: Market Dynamics and Financial Trajectory

Ephedrine sulfate is an older, regulated small-molecule decongestant/bronchodilator and a key precursor in illicit manufacture of controlled substances, which drives both commercial friction and demand volatility across geographies. Its market trajectory is shaped less by new clinical differentiation and more by regulation, supply chain stability for regulated raw materials, and substitution by alternatives (including non-controlled bronchodilators and combination cold-and-cough products). On the financial side, revenue outcomes in most countries track (1) regulatory access constraints, (2) prescribing and OTC mix shifts, and (3) procurement cycles for bulk APIs and finished dosage forms.

What drives market demand for ephedrine sulfate?

Demand is concentrated in three use cases, with regulation determining how much flows through legitimate channels.

• Respiratory symptom management

  • Historically used as a bronchodilator and decongestant.
  • Market pull comes from chronic obstructive pulmonary disease (COPD) management patterns in some regions, and from acute respiratory symptom products in OTC channels where permitted.

• Perioperative and anesthesia-adjunct use

  • Ephedrine is used for hemodynamic support in certain anesthesia settings in some markets.
  • Demand here is more stable than OTC cold remedies but still sensitive to guideline shifts and availability of alternatives (including direct-acting vasopressors in some healthcare systems).

• Manufacturing and chemical supply chain

  • Ephedrine and related alkaloid sources intersect with regulated chemical supply chains.
  • Legitimate procurement depends on licensing, auditing, and controlled logistics.

Regulatory tightness changes the balance between these streams. Where access is restricted, substitute products gain share; where permitted, hospital and OTC channels can re-accelerate.

What regulatory forces shape pricing and availability?

Ephedrine sulfate is regulated as a controlled precursor in many jurisdictions. That status impacts pricing and availability through compliance friction and supply chain controls.

Core mechanisms

• Licensing and transaction controls

  • Companies must manage licenses for import, distribution, and end-use verification.
  • This increases lead times and can create intermittent shortages or price spikes when compliance capacity is constrained.

• Monitoring and enforcement

  • Stricter monitoring raises the cost of doing business and can limit tender participation for some suppliers.

• Diversion risk pricing

  • In markets with higher enforcement intensity, wholesalers and manufacturers embed risk premia into contracts, especially for bulk API and semi-finished intermediates.

Market effect

• Supply becomes less elastic than demand.
• Price volatility rises around policy shifts, enforcement campaigns, and procurement cycles.
• Commercial growth depends more on access and manufacturing continuity than on product innovation.

How do product substitution dynamics affect volume?

Ephedrine sulfate competes in therapeutic adjacency, not in drug-innovation novelty. The substitutes that matter are usually faster-acting bronchodilators, non-ephedrine decongestants, and alternative vasopressors in clinical settings.

Substitution vectors

• Cold-and-cough formulations

  • OTC mix shifts toward products with lower diversion concerns and/or different active ingredients.
  • Combination formulations reduce reliance on ephedrine-containing products where regulatory status restricts marketing.

• Respiratory drugs

  • In bronchodilation, newer agents and established inhaled therapies can displace older systemic sympathomimetics depending on local formularies.

• Perioperative vasopressor preference

  • Some anesthesia protocols favor alternatives, which reduces per-case demand even when ephedrine remains on formularies.

Net: substitution typically caps long-term unit growth, which shifts the financial story toward stable cash flow with periodic volatility.

What supply chain risks can change the market quickly?

Ephedrine sulfate supply is sensitive to:

• Bulk API availability from licensed sources
• Regulated chemical transport and documentation readiness
• Regional enforcement changes that slow distribution

Commercial outcomes

• Short-term procurement surges when approved inventory gets constrained.
• Price compression when multiple licensed suppliers can re-enter tenders.
• Margin swings for distributors and lower-margin brand distributors when lead times extend.

In effect, the market behaves like a controlled-commodity rather than a conventional branded pharmaceutical market.

---

Financial Trajectory: Revenue, Margins, and Investment-Likelihood

How does the financial trajectory usually look for ephedrine sulfate products?

For older regulated actives, the financial pattern typically aligns to:

• Stable baseline revenue where permitted for specific therapeutic uses
• Regulated-channel concentration that limits expansion opportunities
• Volatility from enforcement and supply constraints
• Limited defensibility because the molecule is off-patent in most mature markets, and value shifts to compliance, manufacturing scale, and supply continuity

Revenue drivers

• Unit volumes driven by permitted channels (hospital tenders, OTC licensing where available, and institutional procurement)
• Price realization driven by availability, compliance costs, and tender competition
• Product mix across API vs finished dosage forms

Margin drivers

• Compliance and QA/QC costs
• Batch yields and manufacturing reliability
• Working capital impact from slower regulated logistics and lead times

Where does upside come from?

Upside is less about clinical expansion and more about operational access:

• Securing tender wins in hospital or institutional segments when supply is constrained.
• Normalizing procurement channels after enforcement-driven shortages.
• Expanding finished dosage form presence only in jurisdictions where regulatory and labeling requirements support continued commercialization.

In many markets, upside is intermittent and tied to supply gaps rather than steady volume growth.

Where does downside come from?

Downside risks are similarly structural:

• Regulatory tightening that reduces permitted use or increases documentation requirements.
• Substitution via alternative therapeutics or formulation changes.
• Supply disruptions due to licensing restrictions, manufacturing downtime, or diverted-supply enforcement that forces curtailment of shipments.

Downside often hits revenue faster than costs can adjust, because regulated procurement delays can’t be quickly rerouted.

---

What does the competitive landscape imply for pricing power?

Is ephedrine sulfate a commodity market?

It is closer to a regulated commodity than an innovation-driven market. Pricing power comes from:

• Licensed manufacturing capacity
• Consistent batch supply
• Ability to pass compliance audits
• Tender execution across institutional buyers

Implication for financial modeling

• Forecasts should treat the market as volume constrained by regulation and supply, with price swings driven by availability.
• Expect limited durable premium pricing unless competitors are constrained or enforcement temporarily tightens.

How do channel structures affect economics?

Economics differ by route to market:

• API sales
  • Higher exposure to raw-material and regulated logistics constraints.
  • Margin typically hinges on scale and reliability.
• Finished dosage forms
  • Adds labeling, packaging, and localized regulatory approvals.
  • Margins can be steadier but expansion is slower due to compliance and commercialization requirements.

---

Investment and R&D Signal: What is investable vs not?

Does ephedrine sulfate attract new drug development investment?

Ephedrine sulfate itself is not a typical platform for new R&D investment because:

• It is an older active ingredient.
• Competitive differentiation is limited in jurisdictions where it is already generic or off-patent.
• The main barriers are regulatory and access rather than clinical opportunity.

Where investment still appears rational

• Manufacturing capacity and compliance leadership (licensed production scale, QA reliability, controlled logistics)
• Formulation and distribution optimization in permitted markets
• Supply chain resilience contracts with stable institutional demand

What is the likely financial payoff profile?

The payoff profile generally looks like:

• Lower upside than novel drugs
• Less dependence on clinical trial risk
• Higher dependence on regulatory execution and supply continuity
• Volatility driven by policy, enforcement, and sourcing constraints

This makes the asset more suited to procurement and operations-focused strategies than to breakthrough R&D investment strategies.

---

Key Takeaways

• Ephedrine sulfate demand is driven by regulated therapeutic uses (respiratory symptoms and some perioperative roles) plus the dynamics of controlled-chemical supply chains.
• Regulation and diversion-risk controls dominate pricing and availability, creating procurement lead-time friction and periodic price volatility.
• Substitution by alternative decongestants/bronchodilators and perioperative vasopressor practice patterns caps sustained volume growth.
• Financial trajectory tends to be stable baseline cash flow in permitted channels with margin sensitivity to compliance cost, manufacturing reliability, and supply constraints.
• Investability is highest for strategies that secure licensed manufacturing and execution capacity, not for clinical differentiation.

---

FAQs

1) What most influences near-term pricing for ephedrine sulfate?

Supply constraints tied to licensed availability and regulated logistics, which can tighten availability quickly and swing tender pricing.

2) Does substitution meaningfully reduce long-term unit growth?

Yes. In many jurisdictions, OTC formulation shifts and respiratory therapy substitution reduce incremental demand growth.

3) Is the market for ephedrine sulfate more like a commodity than a specialty drug?

It behaves like a regulated commodity where pricing power depends on licensed capacity and supply continuity rather than innovation.

4) What are the biggest operational risks to revenue?

Compliance-driven shipment delays, licensing constraints, and manufacturing interruptions that limit the ability to meet institutional demand.

5) What type of strategy tends to perform best financially?

Operations and supply execution strategies, including securing reliable procurement pipelines and tender readiness within regulated channels.

---

References

[1] International Narcotics Control Board (INCB). Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances: Ephedrine. INCB reports and precursor monitoring materials.
[2] United Nations Office on Drugs and Crime (UNODC). Guidance on monitoring of precursors and controlled substances. UNODC publications on precursor control and diversion.
[3] U.S. Drug Enforcement Administration (DEA). List I chemical regulatory materials and ephedrine/ephedrine-related controls. DEA chemical control documentation.